Search PubMed⌕ Search

Biomedical subjects

A Schnabel

Publications and source records attributed to A Schnabel.

112 records · Page 7Linked to original sources
PubMedDate not supplied

Post-ischemic myocardial function after pre-ischemic application of propranolol or verapamil.

The influence of pre-ischemic treatment with propranolol (0.8 mg/kg bw) or with verapamil (0.1 mg/kg bw) on myocardial O2 consumption and on coronary resistance after cardioplegic arrest (300 minutes at 22 degrees - 24 degrees C) was investigated, using a Langendorff technique in open chest experiments (canine hearts). For myocardial protection histidine buffered Bretschneider solution was used, while for standardization all hearts were postischemically reperfused with a modified Tyrode solution at 35 degrees C. Both drugs were given intravenously in two fractions, 60 and 30 minutes before the onset of cardioplegic perfusion; a third group was not pretreated. Although the verapamil group had the lowest O2 consumption post-ischemically, the most impressive results were found in coronary resistance. Propranolol significantly diminished coronary resistance (p less than 0.05), while verapamil distinctly enhanced it compared to the non treated group. The "membrane labilizing" effect of verapamil combined with calcium-free cardioplegic solution was confirmed by a massive postischemic myocardial sodium uptake.

Animals↗
PubMedDate not supplied

[Side effects and efficiency of 15 mg and 25 mg methotrexate per week in chronic polyarthritis].

To examine the rate of side effects and the dose dependence of side effects 185 consecutive patients with active rheumatoid arthritis were randomized to receive 15 mg (group A) or 25 mg (group B) methotrexate (MTX) per week and studied prospectively over 12 months. Dose adjustments were performed according to tolerability and efficacy. With 168 patients eligible for evaluation the rate of withdrawal for any reason was 26% in group A and 27% in B. Withdrawal due to side effects occurred in 16% versus 18%, dose reduction due to side effects in 10% versus 9%. The higher dose was associated with a significantly higher rate of gastrointestinal side effects (28% vs. 17%, p < 0.05) and a tendency for more frequent elevations of transaminases. Other side effects were not dose dependent. A significantly higher rate of dose reduction due to improvement (35% versus 10%, p < 0.001), a more rapid decline of morning stiffness, and a higher number of patients reporting marked improvement are evidence in favour of higher therapeutic efficacy of the higher dose. In conclusion, an initial dose of 25 mg MTX/week is not associated with a higher rate of limiting side effects as compared with 15 mg/week. The efficacy of doses up to 25 mg/week should be examined in more detail.

Adult↗
PubMedDate not supplied

[ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure].

The ANCA-associated vasculitides (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis) are characterized by a broad spectrum of clinical manifestations and a highly variable clinical course. Due to greatly improved diagnostic techniques the number of newly diagnosed cases has increased rapidly within the past few years. This facilitated more individualized treatment and led to the concept of stage-adapted treatment. Immunodiagnostic parameters are being utilized increasingly to supplement clinical and radiological findings. Inflammatory lesions are visualized by, for example, e.g. rhinoscopy, sinoscopy, and bronchoscopy or by radiological techniques including cranial and skeletal muscle magnetic resonance imaging, pulmonary high-resolution computed tomography, and digital subtraction angiography. These techniques not only serve to detect the extent of tissue and organ involvement, but also to direct bioptic procedures. Conventional histopathology must be supplemented by immunohistology in order to distinguish between the "immune complex vasculitides" and the ANCA-associated "pauci-immune vasculitides".

Antibodies, Antineutrophil Cytoplasmic↗